About: Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Mitchell Goldstein et al published December 2018 in American Journal of Perinatology

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2018 (uk) im Dezember 2018 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Mitchell Goldstein et al published December 2018 in American Journal of Perinatology (en)
publication date	wds:Q59358484-898A7F05-E801-4215-A14F-8639C01432AF
publication date	2018-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q59358484-26A54DF6-8A70-46AD-BD6D-7C88E18E4065
language of work or name	English
cites work	wds:Q59358484-02C800B2-195F-4A72-8A3D-4954D5626C19 wds:Q59358484-236E650A-6607-4186-9FB9-273CC94116B2 wds:Q59358484-2ECFD2C9-0739-47EE-B602-CB3943EA4407 wds:Q59358484-306B9378-754E-42B2-834D-CA55C16D72F3 wds:Q59358484-342912A2-2FFB-4A9A-9802-69944522A210 wds:Q59358484-37957370-4E9C-4A7B-84B2-589F88975EE9 wds:Q59358484-3CBB1560-6760-4BE5-9B45-0C0AF0B03389 wds:Q59358484-43CD2BD9-97FF-465A-A9C6-B9FBB1EAD41F wds:Q59358484-48C20C42-A075-42C9-A972-4E711CE95E67 wds:Q59358484-493E62B4-B211-4F81-8142-F06FE2AB6DD1 wds:Q59358484-4954EDF0-672E-44B6-89BA-0FCE4CBB1205 wds:Q59358484-53031FD2-BC18-4A7E-A28C-52BC587B55C9 wds:Q59358484-5388D10B-617F-4FBF-A059-54EB31DCEF79 wds:Q59358484-671EB5DC-2F09-4A51-9C91-6A264B89F9D1 wds:Q59358484-6AB21B87-0B73-4C16-83E8-A323C0A81D65 wds:Q59358484-6BF6BB3D-9ABC-40E9-B3DC-3C7F206C3A60 wds:Q59358484-73B9D774-57B7-4FAE-AC55-83AABABC42DC wds:Q59358484-94C83262-0345-4666-A2A0-21CA88165E38 wds:Q59358484-9B07E79F-B4FD-4B0B-A4C3-14203A2554D5 wds:Q59358484-A076111E-6658-4273-9010-7A4AF761353E wds:Q59358484-A0B192A5-938B-449F-835D-E517AFED065E wds:Q59358484-A4428387-A93D-4207-8FB4-7E4BADE5954E wds:Q59358484-A8124093-6981-4B60-BA84-8BB20007CEC0 wds:Q59358484-A9CC1B2F-A452-4922-AF13-96216DD4623A wds:Q59358484-B2E0E42C-4E2D-41A8-9950-B9EEB30B238E wds:Q59358484-BD7A47A1-5BC7-4954-AFA9-DCC67ABAB7F2 wds:Q59358484-C3FC68D7-5553-46B7-A3AB-FF370C2AB3AF wds:Q59358484-CFFB559A-5536-43C2-8351-45605D9DBBC4 wds:Q59358484-D5311084-BD4E-40DF-8086-ADF7ED518200 wds:Q59358484-E704DA41-B895-4F49-B2E7-9F6ED24D6363 wds:Q59358484-F77B0514-89CE-40D8-B48A-84146C763CCB wds:Q59358484-FFD63543-F0F4-4EE8-A24D-2D4578DEFAAA
cites work	Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease Respiratory syncytial virus and recurrent wheeze in healthy preterm infants Rates of hospitalization for respiratory syncytial virus infection among children in medicaid Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Serum-gamma-G-globulin levels in normal premature, post-mature, and "small-for-dates" newborn babies Viral and host factors in human respiratory syncytial virus pathogenesis Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age. Human lung growth in late gestation and in the neonate Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis Healthcare costs within a year of respiratory syncytial virus among Medicaid infants Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States. Impact of the 2014 American Academy of Pediatrics guidance on respiratory syncytial virus and bronchiolitis hospitalization rates for infants born prematurely Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
author name string	wds:Q59358484-11498D39-9D1D-4C1C-B495-339A3068BDA1 wds:Q59358484-1400FC18-6BD6-4955-B155-77E5F87B3F79 wds:Q59358484-48A9DC03-5EFA-42C2-9279-5E0E6ADBA8E8 wds:Q59358484-4D5B436E-8020-4EC6-B32C-31916925E26C wds:Q59358484-762AC680-E5F2-495D-9A90-1C3D259AE791 wds:Q59358484-8D4CC7D9-68E8-4FA3-8A41-EB035034EDED wds:Q59358484-9B73994C-7BC5-4ACF-866C-0646E3F3EE7A wds:Q59358484-D1019290-4F7F-44BC-86BC-A659C070E96D wds:Q59358484-F1F269C8-ADA5-4939-B677-2BCC53CA7644
author name string	Jaime Fergie Mitchell Goldstein Gregory M Lenhart Sally W Wade Leonard R Krilov Amanda M Kong Kimmie K McLaurin Adam Bloomfield David Diakun
rdfs:label	Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 (en) Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 (nl)
skos:prefLabel	Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 (en) Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 (nl)
name	Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 (en) Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 (nl)
title	wds:Q59358484-D4E07C2F-BC14-4979-BB2C-6B9D13AF7AE3
title	Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016 (en)
page(s)	wds:Q59358484-1F10E7F2-25A5-4019-9AEA-53FE0449FE23

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software